PRMT3 and cancer: We found that Prmt3-KO more profoundly delayed tumor progression in immune-competent mice than in immune-deficient mice for both clones (Fig. 3A–D and Supplementary Fig. 5B, C), suggesting that in addition to the cancer cell-intrinsic functions of PRMT3, T cell-mediated anti-tumor immunity also contributed to the observed delay in tumor growth in Prmt3-KO cells.